RKDA vs XBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 17, 2026

RKDA

49.0
AI Score
VS
RKDA Wins

XBIO

26.7
AI Score

Investment Advisor Scores

RKDA

49score
Recommendation
HOLD

XBIO

27score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric RKDA XBIO Winner
Revenue 2.54M 1.47M RKDA
Net Income -10.65M -1.39M XBIO
Net Margin -418.8% -94.5% XBIO
Operating Income -1.27M -1.47M RKDA
ROE -1682.6% -22.8% XBIO
ROA -180.7% -19.9% XBIO
Total Assets 5.89M 6.97M XBIO
Current Ratio 3.49 7.43 XBIO

Relative Price Performance (Last 90 Days)

RKDA 1M: -32.8% · 3M: -52.9% XBIO 1M: +14.7% · 3M: +4.8%

Current Technical Phase

RKDA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -16.0%), weak momentum, RSI 32

RSI (14): 31.6 · Price: $0.45

XBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 61

RSI (14): 60.5 · Price: $3.19

Fundamentals Snapshot

Metric RKDA XBIO
Market Cap
Forward P/E -0.2 -9.7
Trailing P/E
Revenue (TTM)
Revenue Growth -0.1% 0.1%
Gross Margin 0.3% 1.0%
Operating Margin -0.7% -1.5%
EPS -5.98 -1.16
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, RKDA is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.